Results 81 to 90 of about 4,657 (129)

Real-World Patient Eligibility for Alzheimer's Disease Anti-Amyloid Therapy in Seven Swedish Memory Clinics. [PDF]

Eur J Neurol
Rosenberg A, Rennie A, Ekman U, Daniilidou M, Hall A, Matton A, Solomon A, Wahlund LO, Kivipelto M, Westman E.   +9 more
europepmc   +1 more source

Corrigendum to "Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181" [The Journal of Prevention of Alzheimer's Disease (2026) 100664]. [PDF]

J Prev Alzheimers Dis
Noguchi-Shinohara M, Muramatsu D, Shima A, Sakashita Y, Tada Y, Yamaguchi H, Komatsu J, Ikeda T, Ono K.   +8 more
europepmc   +1 more source

Therapeutic Time Window of Disease-Modifying Therapy for Early Alzheimer's Disease in Japanese Individuals: Analysis Based on J-ADNI Study. [PDF]

Geriatr Gerontol Int
Nakashima S, Sato K, Niimi Y, Ihara R, Suzuki K, Iwata A, Satake W, Iwatsubo T, Japanese Alzheimer's Disease Neuroimaging Initiative.   +8 more
europepmc   +1 more source

Comparison of double-blind and open-label decline rates in lecanemab and donanemab trials in Alzheimer's disease. [PDF]

BMJ Neurol Open
Dwivedi AK, Imbimbo BP, Abanto J, Espay AJ.   +3 more
europepmc   +1 more source

Further data to address the Alzheimer's coverage with evidence development questions. [PDF]

Alzheimers Dement
Boustani M, Klein EG, Zimmer JA, Wang H, Engle SE, Phipps A, Japha M, Schilling T, Hartry A, Alzheimer's Disease Neuroimaging Initiative.   +9 more
europepmc   +1 more source

Prospective evaluation of systemic coagulation function during anti-amyloid monoclonal antibody therapy in Alzheimer's disease. [PDF]

J Thromb Thrombolysis
Curd BC, Tolley ND, Santo M, Foster J, Leardini-Tristão M, Jacob S, Benzon H, Ye X, Shah SJ, Supiano MA, Rondina MT, Frost NA, Campbell RA, Parks AL.   +13 more
europepmc   +1 more source

Demographic and Clinical Characteristics of Patients Treated With Lecanemab Stratified by Amyloid-Related Imaging Abnormality Status. [PDF]

Cureus
Rohatgi S, Younan CM, Martinez Imbett RE, Ford JN, Wleklinski M, Zhu S, Romero J.   +6 more
europepmc   +1 more source

From trial population to treated population: why EU-eligible subgroup analyses matter for anti-amyloid immunotherapy. [PDF]

J Prev Alzheimers Dis
Grimmer T.
europepmc   +1 more source

Lecanemab use for early Alzheimer disease in Canada. [PDF]

CMAJ
Weiss SM, Watt JA, Ewa V, Straus SE.
europepmc   +1 more source